The data presented here showing that a protease-resistant IGFBP4 blocks IGF activity and therefore tumour growth and angiogenesis, suggests that protease-resistant IGFBP4 may have value as a novel breast cancer treatment. This evidence concerns the gene IGF1 and neoplasm.